KYTX
Kyverna Therapeutics, Inc. Common Stock
NASDAQ: KYTX · HEALTHCARE · BIOTECHNOLOGY
$5.16
-1.15% today
Updated 2026-11-03
Market cap
$333.34M
P/E ratio
—
P/S ratio
3,513.34x
EPS (TTM)
$-2.93
Dividend yield
—
52W range
$5 – $14
Volume
0.9M
Kyverna Therapeutics, Inc. Common Stock (KYTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $-22.16M | $-36.11M | $-52.41M | $-114.25M | $-153.71M |
| Capital expenditures | $1.29M | $768000.00 | $621000.00 | $2.21M | $5000.00 |
| Depreciation | — | — | — | — | — |
| Stock-based comp | $7.25M | $929000.00 | $2.22M | $8.36M | $10.08M |
| Free cash flow | $-23.44M | $-36.88M | $-53.03M | $-116.45M | $-153.72M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — |
| Dividends paid | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt repayment | — | — | — | — | — |
| Net change in cash | — | — | — | — | — |
Frequently asked questions
How much free cash flow does KYTX generate?
KYTX produced $-153.72M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is KYTX's balance sheet healthy?
KYTX holds $124.09M in cash and equivalents against $24.74M in long-term debt, on $232.28M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.